Mizuho Boosts Immix Biopharma (NASDAQ:IMMX) Price Target to $26.00

Immix Biopharma (NASDAQ:IMMX) had its price target hoisted by Mizuho from $15.00 to $26.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm currently has an “outperform” rating on the stock. Mizuho’s target price indicates a potential upside of 117.41% from the stock’s previous close.

IMMX has been the topic of several other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Immix Biopharma in a research note on Friday, July 17th. Lifesci Capital started coverage on Immix Biopharma in a research report on Wednesday, June 17th. They issued an “outperform” rating and a $19.00 target price for the company. Morgan Stanley lowered their price target on Immix Biopharma from $20.00 to $19.00 and set an “overweight” rating for the company in a report on Tuesday, August 11th. Citigroup reissued a “market outperform” rating on shares of Immix Biopharma in a research report on Friday, August 14th. Finally, HC Wainwright raised their price objective on Immix Biopharma from $20.00 to $25.00 and gave the stock a “buy” rating in a research note on Monday, August 10th. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Immix Biopharma has an average rating of “Moderate Buy” and a consensus target price of $22.86.

Immix Biopharma Trading Down 2.1%

IMMX stock traded down $0.25 during mid-day trading on Tuesday, hitting $11.96. 157,453 shares of the company were exchanged, compared to its average volume of 1,268,328. The firm has a fifty day simple moving average of $11.33 and a 200 day simple moving average of $10.00. The company has a market capitalization of $855.53 million, a PE ratio of -13.67 and a beta of 0.20. Immix Biopharma has a twelve month low of $1.94 and a twelve month high of $15.10.

Immix Biopharma (NASDAQ:IMMX) last issued its earnings results on Friday, August 7th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01). As a group, sell-side analysts anticipate that Immix Biopharma will post -0.74 earnings per share for the current year.

Institutional Trading of Immix Biopharma

Hedge funds have recently made changes to their positions in the stock. Private Advisor Group LLC grew its position in shares of Immix Biopharma by 9.5% during the first quarter. Private Advisor Group LLC now owns 34,725 shares of the company’s stock worth $316,000 after acquiring an additional 3,000 shares during the last quarter. Legal & General Group Plc acquired a new stake in shares of Immix Biopharma in the second quarter valued at approximately $41,000. Allworth Financial LP acquired a new stake in shares of Immix Biopharma in the fourth quarter valued at approximately $30,000. California State Teachers Retirement System bought a new stake in shares of Immix Biopharma during the second quarter valued at approximately $566,000. Finally, Compass Financial Management LLC bought a new stake in shares of Immix Biopharma during the second quarter valued at approximately $56,000. Institutional investors own 11.26% of the company’s stock.

Immix Biopharma Company Profile

Immix Biopharma, Inc (NASDAQ: IMMX) is a clinical-stage biopharmaceutical company developing cell therapies for cancer and autoimmune diseases. The company focuses on treatments designed to target disease-associated cells and address serious conditions with limited therapeutic options.

Its lead product candidate is NXC-201, an autologous chimeric antigen receptor T-cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA). NXC-201 is being investigated for relapsed or refractory AL amyloidosis and multiple myeloma, two diseases involving abnormal plasma cells.